Alexiades-Armenakas Macrene
Department of Dermatology, Yale University School of Medicine, New York, NY 10021, USA.
Clin Dermatol. 2006 Jan-Feb;24(1):16-25. doi: 10.1016/j.clindermatol.2005.10.027.
Photodynamic therapy (PDT) has evolved since its inception at the beginning of the 20th century, when it was defined as an oxygen-dependent reaction between a photosensitizing dye and light. Photosensitizers and light sources have since been continually optimized for distinct applications and tissues. Systemic porphyrins, such as hematoporphyrin, were the first photosensitizers to be used, mostly to treat tumors. The first light sources used were broad-band, noncoherent lights, such as quartz, xenon, tungsten, or halogen lamps. The wavelengths of light chosen were based upon the absorption spectrum of porphyrins: blue because the largest peak is at 400 nm (the Soret band) and red because of its greater penetration depth but lesser absorption at 650 nm (a Q band). Systemic photosensitizers caused prolonged photosensitivity, and broad-band light sources had limitations and side effects. The development of topical photosensitizers, such as 5-aminolevulinic acid, and the advent of lasers in recent years have advanced PDT for cutaneous use. In the 1990s, red lasers were applied to PDT because of their increased skin penetration despite lesser absorption by porphyrins. Broad-band blue light and red light have been studied extensively, the former achieving Food and Drug Administration approval in combination with topical aminolevulinic acid for the treatment of actinic keratosis in 1997. These lasers and light sources caused significant side effects, such as discomfort, erythema, crusting, blistering, and dyspigmentation. The recent application of the long-pulsed pulsed dye laser (595 nm) after topical aminolevulinic acid greatly minimized side effects without compromising efficacy. Long-pulsed pulsed dye laser-mediated PDT has since been shown to be effective in treatment of actinic keratosis, actinic cheilitis, sebaceous hyperplasia, lichen sclerosus, and, most recently, acne vulgaris. Finally, intense pulsed light sources have been introduced to PDT for the treatment of photodamage and acne, offering advantages of versatility in wavelengths and applications.
光动力疗法(PDT)自20世纪初诞生以来不断发展,当时它被定义为一种光敏染料与光之间的氧依赖性反应。从那时起,光敏剂和光源就一直在针对不同的应用和组织进行持续优化。全身性卟啉,如血卟啉,是最早使用的光敏剂,主要用于治疗肿瘤。最初使用的光源是宽带非相干光,如石英灯、氙灯、钨灯或卤素灯。所选择的光波长基于卟啉的吸收光谱:选择蓝光是因为最大峰值在400nm(Soret带),选择红光则是因为其穿透深度更大,但在650nm处吸收较小(一个Q带)。全身性光敏剂会导致长时间的光敏感,而宽带光源存在局限性和副作用。近年来,局部用光敏剂如5-氨基酮戊酸的开发以及激光的出现推动了用于皮肤的光动力疗法的发展。在20世纪90年代,红色激光被应用于光动力疗法,因为尽管卟啉对其吸收较少,但它对皮肤的穿透力增强。宽带蓝光和红光已得到广泛研究,前者在1997年与局部用氨基酮戊酸联合使用时获得了美国食品药品监督管理局的批准,用于治疗光化性角化病。这些激光和光源会引起显著的副作用,如不适、红斑、结痂、水疱和色素沉着。局部用氨基酮戊酸后近期应用的长脉冲染料激光(595nm)在不影响疗效的情况下极大地减少了副作用。此后,长脉冲染料激光介导的光动力疗法已被证明对光化性角化病、光化性唇炎、皮脂腺增生、硬化性苔藓以及最近的寻常痤疮有效。最后,强脉冲光源已被引入光动力疗法用于治疗光损伤和痤疮,在波长和应用方面具有通用性优势。